JL Blum

Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline <i>BRCA</i> mutation

Jennifer K. Litton, HS Rugo, Johannes Ettl et al. · Cancer Research · 2018 · 50 citations

Medicine, Oncology, Pharmacology +15

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

Joyce O’Shaughnessy, D Paul, Christopher Stokoe et al. · Cancer Research · 2010 · 39 citations

Medicine, Oncology, Pharmacology +17

Phase II trial of weekly <i>nab-</i>paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer

Michael A. Danso, JL Blum, N. J. Robert et al. · Journal of Clinical Oncology · 2008 · 31 citations

Medicine, Oncology, Pharmacology +13

PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.

GL Wright, JL Blum, LK Krekow et al. · Cancer Research · 2011 · 20 citations

Medicine, Oncology, Pharmacology +17

Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial.

John D. Hainsworth, Stephen E. Jones, Robert Mennel et al. · Journal of Clinical Oncology · 1996 · 18 citations

Medicine, Oncology, Pharmacology +14